Transcriptome-level microarray expression profiling implicates IGF-1 and Wnt signalling dysregulation in the pathogenesis of thyroid-associated orbitopathy

Journal of Clinical Pathology

Volumn 65, Issue 7, 2012, Pages 608-613

  Ezra, Daniel G ^a,b,c   Krell, Jonathan ^c   Rose, Geoffrey E ^a   Bailly, Maryse ^a,b   Stebbing, Justin ^c   Castellano, Leandro ^c  

^a MOORFIELDS EYE HOSPITAL   (United Kingdom)

^b UNIVERSITY COLLEGE LONDON   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENTARY DNA; FAT; INSULIN RECEPTOR SUBSTRATE 2; INTERLEUKIN 27; ORBITAL FAT; PROTEIN C JUN; SOMATOMEDIN B RECEPTOR; SOMATOMEDIN BINDING PROTEIN; SOMATOMEDIN BINDING PROTEIN 6; SOMATOMEDIN C; SUPPRESSOR OF CYTOKINE SIGNALING 3; TRANSCRIPTION FACTOR; UNCLASSIFIED DRUG; WNT PROTEIN; WNT5A PROTEIN;

ADH1B GENE; ADULT; AGED; AIF1 GENE; AKR1C1 GENE; ARTICLE; BBS7 GENE; BCL11A GENE; C14ORF180 GENE; CD28 GENE; CD300A GENE; CLEC11A GENE; CLINICAL ARTICLE; CMBL GENE; COL12A1 GENE; CONTROLLED STUDY; CTSC GENE; DAAM1 GENE; DKK3 GENE; DOWN REGULATION; ENDOCRINE OPHTHALMOPATHY; ERAP2 GENE; FABP4 GENE; FEMALE; FOXL2 GENE; FZD7 GENE; GENE; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; IFI16 GENE; IFNAR2 GENE; IGF1 GENE; IGFBP6 GENE; IGLV1 44 GENE; IGSF10 GENE; IL17D GENE; IL7R GENE; IRS2 GENE; ITGBL1 GENE; JUN GENE; LYZ GENE; MALE; MFAP5 GENE; MICROARRAY ANALYSIS; ORBIT DISEASE; ORBIT INFLAMMATION; PATHOGENESIS; PLCB1 GENE; PRIORITY JOURNAL; PTPRC GENE; SFRP4 GENE; SGK1 GENE; SLC20A1 GENE; SLC22A16 GENE; SLC2A14 GENE; SOCS3 GENE; ST8SIA4 GENE; TGFBR1 GENE; THY1 GENE; THYROTOXICOSIS; TMEM111 GENE; TRANSCRIPTOMICS; UPREGULATION; WNT5A GENE;

ADULT; AGED; CASE-CONTROL STUDIES; DOWN-REGULATION; GENE EXPRESSION PROFILING; GRAVES OPHTHALMOPATHY; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; ORBIT; ORBITAL DISEASES; SIGNAL TRANSDUCTION; UP-REGULATION; WNT PROTEINS;

EID: 84863599014     PISSN: 00219746     EISSN: 14724146     Source Type: Journal    
DOI: 10.1136/jclinpath-2012-200719     Document Type: Article

References (32)

1. Trobe JD. Optic nerve involvement in dysthyroidism. Ophthalmology 1981;88:488-92. (Pubitemid 12195218)
2. Tallstedt L, Lundell G, Torring O, et al. Occurrence of ophthalmopathy after treatment for Graves' hyperthyroidism. The Thyroid Study Group. N Engl J Med 1992;326:1733-8.
3. Hufnagel TJ, Hickey WF, Cobbs WH, et al. Immunohistochemical and ultrastructural studies on the exenterated orbital tissues of a patient with Graves' disease. Ophthalmology 1984;91:1411-19. (Pubitemid 15208915)
4. Sorisky A, Pardasani D, Gagnon A, et al. Evidence of adipocyte differentiation in human orbital fibroblasts in primary culture. J Clin Endocrinol Metab 1996;81:3428-31. (Pubitemid 26296229)
5. Naik VM, Naik MN, Goldberg RA, et al. Immunopathogenesis of thyroid eye disease: emerging paradigms. Surv Ophthalmol 2010;55:215-26.
6. Kumar S, Coenen MJ, Scherer PE, et al. Evidence for enhanced adipogenesis in the orbits of patients with Graves' ophthalmopathy. J Clin Endocrinol Metab 2004;89:930-5. (Pubitemid 38269913)
7. Pritchard J, Horst N, Cruikshank W, et al. Igs from patients with Graves' disease induce the expression of T cell chemoattractants in their fibroblasts. J Immunol 2002;168:942-50. (Pubitemid 34049599)
8. Smith TJ. The putative role of fibroblasts in the pathogenesis of Graves' disease: evidence for the involvement of the insulin-like growth factor-1 receptor in fibroblast activation. Autoimmunity 2003;36:409-15. (Pubitemid 37160530)
9. Smith TJ, Hoa N. Immunoglobulins from patients with Graves' disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab 2004;89:5076-80. (Pubitemid 39391451)
10. Tsui S, Naik V, Hoa N, et al. Evidence for an association between thyroid-stimulating hormone and insulin-like growth factor 1 receptors: a tale of two antigens implicated in Graves' disease. J Immunol 2008;181:4397-405.
11. Douglas RS, Gianoukakis AG, Kamat S, et al. Aberrant expression of the insulin-like growth factor-1 receptor by T cells from patients with Graves' disease may carry functional consequences for disease pathogenesis. J Immunol 2007;178:3281-7.
12. Douglas RS, Naik V, Hwang CJ, et al. B cells from patients with Graves' disease aberrantly express the IGF-1 receptor: implications for disease pathogenesis. J Immunol 2008;181:5768-74.
13. Kumar S, Leontovich A, Coenen MJ, et al. Gene expression profiling of orbital adipose tissue from patients with Graves' ophthalmopathy: a potential role for secreted frizzled-related protein-1 in orbital adipogenesis. J Clin Endocrinol Metab 2005;90:4730-5. (Pubitemid 41159365)
14. Planck T, Parikh H, Brorson H, et al. Gene expression in Graves' ophthalmopathy and arm lymphedema: similarities and differences. Thyroid 2011;21:663-74.
15. Lantz M, Vondrichova T, Parikh H, et al. Overexpression of immediate early genes in active Graves' ophthalmopathy. J Clin Endocrinol Metab 2005;90:4784-91. (Pubitemid 41159372)
16. Chen MH, Liao SL, Tsou PL, et al. Lysosome-related genes are regulated in the orbital fat of patients with graves' ophthalmopathy. Invest Ophthalmol Vis Sci 2008;49:4760-4.
17. Xie Y, Xiao G, Coombes KR, et al. Robust gene expression signature from formalin-fixed paraffin-embedded samples predicts prognosis of non-small-cell lung cancer patients. Clin Cancer Res 2011;17:5705-14.
18. Irizarry RA, Hobbs B, Collin F, et al. Exploration, normalization, and summaries of high density oligonucleotide array probe level data. Biostatistics 2003;4:249-64.
19. Logan CY, Nusse R. The Wnt signaling pathway in development and disease. Annu Rev Cell Dev Biol 2004;20:781-810. (Pubitemid 39488658)
20. Nguyen AV, Albers CG, Holcombe RF. Differentiation of tubular and villous adenomas based on Wnt pathway-related gene expression profiles. Int J Mol Med 2010;26:121-5.
21. Christodoulides C, Lagathu C, Sethi JK, et al. Adipogenesis and WNT signalling. Trends Endocrinol Metab 2009;20:16-24.
22. van Amerongen R, Mikels A, Nusse R. Alternative Wnt signaling is initiated by distinct receptors. Sci Signal 2008;1:re9.
23. Mikels AJ, Nusse R. Purified Wnt5a protein activates or inhibits beta-catenin-TCF signaling depending on receptor context. PLoS Biol 2006;4:e115.
24. Bennett CN, Ross SE, Longo KA, et al. Regulation of Wnt signaling during adipogenesis. J Biol Chem 2002;277:30998-1004. (Pubitemid 34970803)
25. Kawano Y, Kypta R. Secreted antagonists of the Wnt signalling pathway. J Cell Sci 2003;116:2627-34. (Pubitemid 36857216)
26. Adams TE, Epa VC, Garrett TP, et al. Structure and function of the type 1 insulin-like growth factor receptor. Cell Mol Life Sci 2000;57:1050-93. (Pubitemid 30598754)
27. Mitsiades CS, Mitsiades NS, McMullan CJ, et al. Inhibition of the insulin-like growth factor receptor-1 tyrosine kinase activity as a therapeutic strategy for multiple myeloma, other hematologic malignancies, and solid tumors. Cancer Cell 2004;5:221-30. (Pubitemid 38402114)
28. Baxter RC, Twigg SM. Actions of IGF binding proteins and related proteins in adipose tissue. Trends Endocrinol Metab 2009;20:499-505.
29. Smith TJ. Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev 2010;62:199-236.
30. Ogihara T, Isobe T, Ichimura T, et al. 14-3-3 protein binds to insulin receptor substrate-1, one of the binding sites of which is in the phosphotyrosine binding domain. J Biol Chem 1997;272:25267-74. (Pubitemid 27415716)
31. Dey BR, Furlanetto RW, Nissley P. Suppressor of cytokine signaling (SOCS)-3 protein interacts with the insulin-like growth factor-I receptor. Biochem Biophys Res Commun 2000;278:38-43.
32. Gamper N, Fillon S, Huber SM, et al. IGF-1 up-regulates K+ channels via PI3-kinase, PDK1 and SGK1. Pflugers Arch 2002;443:625-34. (Pubitemid 34185067)